A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.

ABSTRACT:

Background

Aberrant Wnt pathway signaling has been implicated in the development of many cancers. Targeting of low-density lipoprotein receptor-related protein 5/6 (LRP5/6) co-receptors inhibits Wnt signaling and may be a novel therapy. BI 905677 is an LRP5/6 antagonist that has demonstrated preclinical antitumor activity.

Patients and methods

This (NCT03604445) was a phase I, dose-escalation study evaluating BI 905677 for patients with advanced solid tumors over two dosing schedules (A: i.v. infusion every 3 weeks, 3-week cycles; B: i.v. infusion every 2 weeks, 4-week cycles). Adult patients were eligible if they had exhausted treatment options and had an Eastern Cooperative Oncology Group performance status of 0-1. The primary endpoints were the maximum tolerated dose (MTD

SUBMITTER: Lenz HJ 

PROVIDER: S-EPMC11670700 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature